Satapathy S, Sood A, Das CK, et al. - In the management of metastatic castration-resistant prostate cancer (mCRPC), researchers assessed the role of ²²⁵ Ac-PSMA (Actinium-225-labeled prostate-specific membrane antigen ligands) radioligand therapy (RLT)in this systematic review. They analyzed 10 articles with 256 patients. Achievement of biochemical response (i.e. ≥ 50% reduction in the serum prostate-specific antigen concentrations from baseline) was noted in 62.8% of patients managed with ²²⁵ Ac-PSMA RLT. The pooled estimates were 9.1 months and 12.8 months, respectively, for median progression-free survival and overall survival. Clinically significant toxicity was limited with grade ≥3 xerostomia, anemia, leucopenia, thrombocytopenia, and nephrotoxicity occurring in 1.2%, 12.3%, 8.3%, 6.3%, and 3.8% of the patients, respectively. Overall, findings demonstrated efficacy as well as safety of ²²⁵ Ac-PSMA RLT as a therapeutic choice for mCRPC.